Gymiso (Misoprostol)

Gymiso is prescribed for several clinical situations where prostaglandin activity is beneficial.

• Prevention of gastric ulcers associated with non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Induction of labor in term pregnancies when cervical readiness is required.
• Medical termination of early pregnancy as part of a regimen with mifepristone.
• Cervical ripening prior to surgical or obstetric procedures.

Misoprostol may cause a range of effects, most of which are related to its action on the gastrointestinal tract and uterus.

Common

• Abdominal cramping or pain.
• Diarrhea or loose stools.
• Nausea or vomiting.
• Fever or chills.
• Headache.

Serious

• Severe uterine bleeding.
• Persistent vomiting leading to dehydration.
• Signs of infection such as fever with abdominal pain.
• Allergic reactions including rash, swelling, or difficulty breathing.

When prescribing Gymiso, clinicians should evaluate patient history and monitor for conditions that could be worsened by prostaglandin effects.

• Avoid use in patients with known hypersensitivity to misoprostol or other prostaglandin analogues.
• Use caution in individuals with cardiovascular disease, hypertension, or asthma.
• Do not administer to women with a viable intrauterine pregnancy unless termination is intended.
• Assess renal or hepatic impairment before initiating therapy.
• Consider the risk of uterine hyperstimulation when used for labor induction.
• Pregnancy category is not established; discuss potential fetal risks with pregnant patients.

Gymiso can interact with other medicines, altering its efficacy or increasing the likelihood of adverse events.

Avoid

• Concurrent use with potent uterotonics (e.g., oxytocin) that may cause excessive uterine contractions.
• Co‑administration with NSAIDs that require gastric protection, as misoprostol may be insufficient alone.
• Combination with drugs that significantly lower blood pressure, such as antihypertensives, may exacerbate hypotension.

Use with caution

• Antacids or proton‑pump inhibitors may reduce the gastric protective effect of misoprostol.
• CYP450‑inducing agents (e.g., rifampin, carbamazepine) could decrease misoprostol plasma levels.
• Drugs that prolong the QT interval should be monitored when used together.